How can Alzheimer's disease blood-based biomarkers reach clinical practice?
(2025) In Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring 17(4).- Abstract
INTRODUCTION: Alzheimer's disease (AD) diagnosis has been based largely on clinical symptoms, despite their limited sensitivity and specificity. Biomarker use was proposed to support a more accurate and timely diagnosis. However, neuroimaging or cerebrospinal fluid (CSF) is rarely used in primary care due to their perceived invasiveness, cost, and need for appropriate infrastructure. Blood-based biomarkers (BBMs) could represent an economical, minimally invasive alternative, but barriers exist to a seamless translation to the clinic. METHODS: Ten international experienced AD clinicians and biomarker experts participated in a diagnostic roundtable to discuss the implementation of BBMs for diagnosing early symptomatic AD. RESULTS: The... (More)
INTRODUCTION: Alzheimer's disease (AD) diagnosis has been based largely on clinical symptoms, despite their limited sensitivity and specificity. Biomarker use was proposed to support a more accurate and timely diagnosis. However, neuroimaging or cerebrospinal fluid (CSF) is rarely used in primary care due to their perceived invasiveness, cost, and need for appropriate infrastructure. Blood-based biomarkers (BBMs) could represent an economical, minimally invasive alternative, but barriers exist to a seamless translation to the clinic. METHODS: Ten international experienced AD clinicians and biomarker experts participated in a diagnostic roundtable to discuss the implementation of BBMs for diagnosing early symptomatic AD. RESULTS: The participants proposed an optimal AD diagnostic pathway and highlighted three main gaps to implementing BBMs for early symptomatic AD diagnosis: limited real-world data, resource gaps, and system barriers. DISCUSSION: Although BBMs could streamline the AD diagnostic pathway, further real-world evidence and collaboration among multiple stakeholders are needed. Highlights: Early symptomatic Alzheimer's disease (AD) diagnosis improves treatment strategy and lowers costs. Currently available biomarkers are not widely used across all clinical settings. Blood-based biomarkers (BBMs) could be a cost-effective, minimally invasive alternative. BBMs could accelerate an accurate AD diagnosis. There are barriers to the inclusion of BBMs in clinical practice.
(Less)
- author
- Perneczky, Robert
; Quevenco, Frances Catherine
; Hendrix, James
; Epelbaum, Stephane
; Teunissen, Charlotte
; van der Flier, Wiesje M.
; Suárez-Calvet, Marc
; Shi, Jiong
; Mielke, Michelle M.
; Iwatsubo, Takeshi
; Palmqvist, Sebastian
LU
and Hansson, Oskar
LU
(Less) - organization
- publishing date
- 2025-10
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Alzheimer's disease, barriers, blood-based biomarkers, diagnosis, diagnostic pathway, guidelines, mild cognitive impairment, population screening
- in
- Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
- volume
- 17
- issue
- 4
- article number
- e70207
- publisher
- Elsevier
- external identifiers
-
- pmid:41189609
- scopus:105020824392
- ISSN
- 2352-8729
- DOI
- 10.1002/dad2.70207
- language
- English
- LU publication?
- yes
- id
- 009ebb6c-508f-4756-aed8-ecb3469648fa
- date added to LUP
- 2025-12-19 11:16:46
- date last changed
- 2025-12-20 03:00:25
@article{009ebb6c-508f-4756-aed8-ecb3469648fa,
abstract = {{<p>INTRODUCTION: Alzheimer's disease (AD) diagnosis has been based largely on clinical symptoms, despite their limited sensitivity and specificity. Biomarker use was proposed to support a more accurate and timely diagnosis. However, neuroimaging or cerebrospinal fluid (CSF) is rarely used in primary care due to their perceived invasiveness, cost, and need for appropriate infrastructure. Blood-based biomarkers (BBMs) could represent an economical, minimally invasive alternative, but barriers exist to a seamless translation to the clinic. METHODS: Ten international experienced AD clinicians and biomarker experts participated in a diagnostic roundtable to discuss the implementation of BBMs for diagnosing early symptomatic AD. RESULTS: The participants proposed an optimal AD diagnostic pathway and highlighted three main gaps to implementing BBMs for early symptomatic AD diagnosis: limited real-world data, resource gaps, and system barriers. DISCUSSION: Although BBMs could streamline the AD diagnostic pathway, further real-world evidence and collaboration among multiple stakeholders are needed. Highlights: Early symptomatic Alzheimer's disease (AD) diagnosis improves treatment strategy and lowers costs. Currently available biomarkers are not widely used across all clinical settings. Blood-based biomarkers (BBMs) could be a cost-effective, minimally invasive alternative. BBMs could accelerate an accurate AD diagnosis. There are barriers to the inclusion of BBMs in clinical practice.</p>}},
author = {{Perneczky, Robert and Quevenco, Frances Catherine and Hendrix, James and Epelbaum, Stephane and Teunissen, Charlotte and van der Flier, Wiesje M. and Suárez-Calvet, Marc and Shi, Jiong and Mielke, Michelle M. and Iwatsubo, Takeshi and Palmqvist, Sebastian and Hansson, Oskar}},
issn = {{2352-8729}},
keywords = {{Alzheimer's disease; barriers; blood-based biomarkers; diagnosis; diagnostic pathway; guidelines; mild cognitive impairment; population screening}},
language = {{eng}},
number = {{4}},
publisher = {{Elsevier}},
series = {{Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring}},
title = {{How can Alzheimer's disease blood-based biomarkers reach clinical practice?}},
url = {{http://dx.doi.org/10.1002/dad2.70207}},
doi = {{10.1002/dad2.70207}},
volume = {{17}},
year = {{2025}},
}